Project Grant HT94252410724

CHERISH Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $889,676 to Indiana University on September 4, 2025, to support the CHERISH project, a clinical research initiative investigating sodium/glucose cotransporter-2 inhibitors (SGLT2i) as a potential therapeutic intervention for Duchenne muscular dystrophy (DMD)-related cardiomyopathy under the Cardiovascular Diseases Research program (CFDA 93.837). The project addresses a critical clinical need, as...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...

The University of Florida Division of Sponsored Research received a $536,800 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund a 3-year exploratory clinical trial to investigate the potential of the drug tadalafil, combined with structured exercise training, to improve muscle pathophysiology and function in individuals with Duchenne...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded UC San Diego a $727,710 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) commencing September 1, 2025, and concluding June 30, 2029, to investigate early drivers and therapeutic targets for arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), a genetic cardiac disease causing sudden death in young populations. The research focuses on desmoplakin (DSP) cardiomyopathy and the...

The Department of the Army Medical Command awarded a $597,916 project grant to Dana-Farber Cancer Institute, Inc. to support research on IRISIN AND THERAPEUTICS FOR DUCHENNE MUSCULAR DYSTROPHY. The grant was awarded on September 30, 2021 with a completion date of September 29, 2023. The funding supports the Military Medical Research and Development program, with the CFDA number 12.420, which aims to transform health care for service members and the public through innovative biomedical research...

REPAIR-ARDS Project Grant Summary Duke University received a $1,364,077 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for June 30, 2030. This grant funds the "Resilience Endotype-Derivation Through Parsimonious Analysis and Causal Inference of Recovery from Acute Respiratory Distress Syndrome (REPAIR-ARDS)" initiative, which addresses...

Summary This National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research project grant (CFDA 93.837) awarded $866,279 to Boston Children's Hospital, with performance in Boston, MA, supports research investigating coordinated protein synthesis and degradation mechanisms during neonatal heart regeneration. The research will generate scientific insights into how neonatal cardiomyocytes maintain protein homeostasis and rapidly adapt to ischemic injury—a regenerative capacity...

The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington $1,657,473 through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic and genomic discovery research identifying molecular targets associated with atrial cardiopathy-related cardiovascular outcomes. The research project, which commenced September 24, 2025 and concludes June 30, 2029, leverages proteomics and genomic methodologies across diverse prevention populations to...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $739,474 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 18, 2025, to investigate the anti-fibrotic roles of stress-induced tRNA-derived small RNAs (tDRs) in cardiac fibrosis. The research will be conducted through May 31, 2030, and focuses on characterizing the mechanisms by which ASP-GTC-3' tDR, a regulatory RNA fragment derived from transfer RNA,...

This $1.44 million Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds research to elucidate the role of purinergic signaling in idiopathic pulmonary fibrosis (IPF) pathogenesis. The research, being conducted at the University of California, San Francisco from August 2025 through May 2029, focuses on understanding how the extracellular ATP (eATP) and P2RX4 receptor signaling axis drives fibroblast...